THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK version of the Market Abuse Regulation (EU) No.596/2014, which forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").
Belluscura plc
("Belluscura", the "Company" or the "Group")
Additional Broker Option - Extension
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, provides an update further to its announcement on 10 February 2023 (headed "Result of Broker Option; Additional Broker Option").
Additional Broker Option
As announced on 10 February 2023, in addition to the $5.8 million (£4.7 million), before expenses raised in Loan Notes in the Placing and Broker Option, Dowgate had identified significant further potential demand for the Loan Notes from placees.
As a result, the Company agreed to issue an additional broker option ("Additional Broker Option") to enable Dowgate to arrange the placing of further loan notes to raise up to an additional approximately $4.2 million (£3.4 million) (the "Additional Broker Option Loan Notes"). This Additional Broker Option was originally scheduled to expire on 28 April 2023. Under the Placing Agreement the Long Stop Date for issuance of the Loan Notes is 12 May 2023, subject to agreement with Dowgate and SPARK.
Interest for significant further demand in the Loan Notes from prospective placees remains, however, Dowgate has advised the Company that these prospective placees require more time, and consequently the Company, Dowgate and SPARK have agreed to allow Dowgate to exercise the Additional Broker Option up to 16 June 2023 and any Additional Broker Option Loan Notes will be issued by the Company on 23 June 2023 with a revised Long Stop Date of 30 June 2023. Accordingly, the Placing Agreement and the Instrument were further amended and restated on 27 April 2023 to extend the deadlines related to the exercise of the Additional Broker Option and the issue of Additional Broker Option Loan Notes thereunder.
Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released on 27 January 2023 and/or 10 February 2023 unless the context requires otherwise.
For further information please contact:
Belluscura plc |
Tel: +44 (0)20 3128 8100 |
Adam Reynolds, Chairman Robert Rauker, Chief Executive Officer Anthony Dyer, Chief Financial Officer |
|
|
|
SPARK Advisory Partners Limited Nominated Adviser |
Tel: +44 (0)20 3368 3550 |
Neil Baldwin |
|
|
|
Dowgate Capital Limited Broker and Bookrunner |
Tel: +44 (0)20 3903 7715 |
James Serjeant / Russell Cook |
|
|
|
MHP Financial PR & Investor Relations |
Tel: +44 (0)20 3128 8100 |
Katie Hunt/Pete Lambie/ Matthew Taylor |
email: Belluscura@mhpgroup.com |